• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why PROCEPT BioRobotics (PRCT) Is Up 9.6% After Reaffirming 2026 Revenue Guidance Despite Wider Losses

    Simply Wall St·08/09/2026 17:28:58
    Listen to the news
    • In the second quarter of 2026, PROCEPT BioRobotics reported sales of US$94.5 million, up from US$79.18 million a year earlier, while its net loss widened to US$26.86 million and it reiterated full-year 2026 revenue guidance of US$390 million to US$410 million alongside an expected net loss of US$96 million to US$91 million.
    • This combination of stronger top-line growth but larger losses, together with analyst concerns about slower procedure trends, competition and legal overhang, has sharpened focus on how efficiently PROCEPT can convert Aquablation adoption into sustainable profitability.
    • We’ll now examine how reaffirmed revenue guidance alongside widening losses could influence PROCEPT BioRobotics’ investment narrative and future expectations.

    Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    PROCEPT BioRobotics Investment Narrative Recap

    To own PROCEPT BioRobotics, you need to believe Aquablation can keep gaining share and justify ongoing investment despite persistent losses. The latest quarter fits that tension: solid sales growth but a wider net loss and reaffirmed revenue guidance keep the main short term catalyst procedure and system adoption intact, while also underscoring the biggest near term risk that rising costs and slower procedure trends could prolong the path to sustainable profitability.

    Against that backdrop, the reaffirmed full year 2026 outlook of US$390 million to US$410 million in revenue, alongside an expected net loss of US$96 million to US$91 million, matters most. It suggests management still sees enough demand momentum to hold its top line targets even as losses widen, which puts extra emphasis on whether hospital adoption, utilization and reimbursement conditions can support that guidance without further eroding investor confidence in the earnings trajectory.

    Yet beneath this growth story, investors should also be aware that competition and pricing pressure could...

    Read the full narrative on PROCEPT BioRobotics (it's free!)

    PROCEPT BioRobotics' narrative projects $607.5 million revenue and $69.6 million earnings by 2029. This requires 21.7% yearly revenue growth and a $179.4 million earnings increase from -$109.8 million today.

    Uncover how PROCEPT BioRobotics' forecasts yield a $22.73 fair value, a 11% upside to its current price.

    Exploring Other Perspectives

    PRCT 1-Year Stock Price Chart
    PRCT 1-Year Stock Price Chart

    Some of the lowest analysts paint a much more cautious picture, assuming about US$607 million of revenue and only US$74 million of earnings by 2029, and they worry that intensifying competition and pricing pressure could keep PROCEPT’s recent combination of strong sales and widening losses from translating into the profitability many shareholders are hoping for, which is why it is worth weighing their view alongside the more optimistic scenarios.

    Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $20.24!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
    • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.